Evidence map›Paper›PMID 40583907›Full record

ArticleAntibody therapeutics2025

Matching placebo development for injectable biologics-a practical tutorial.

Lun Xin, Zhe Zhang, Kushan Shah, Venus Hashemi, Xuanyue Li, Grace Qin, Steven Ren, Wei Chen, Yunsong Li

Abstract read
In one paragraph

Article in Antibody therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lun XinBioDev Department, WuXi Biologics, 1 Cedarbrook Dr, Cranbury, NJ 08512, United States.
Zhe ZhangBioDev Department, WuXi Biologics, 1 Cedarbrook Dr, Cranbury, NJ 08512, United States.
Kushan ShahBioDev Department, WuXi Biologics, 1 Cedarbrook Dr, Cranbury, NJ 08512, United States.
Venus HashemiBioDev Department, WuXi Biologics, 1 Cedarbrook Dr, Cranbury, NJ 08512, United States.
Xuanyue LiBioDev Department, WuXi Biologics, 1 Cedarbrook Dr, Cranbury, NJ 08512, United States.
Grace QinBioDev Department, WuXi Biologics, 1 Cedarbrook Dr, Cranbury, NJ 08512, United States.
Steven RenCMC Management, WuXi Biologics, 1 Cedarbrook Dr, Cranbury, NJ 08512, United States.
Wei ChenCMC Management, WuXi Biologics, 1 Cedarbrook Dr, Cranbury, NJ 08512, United States.
Yunsong LiBioDev Department, WuXi Biologics, 1 Cedarbrook Dr, Cranbury, NJ 08512, United States.ORCID https://orcid.org/0009-0009-0270-7345

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In drug development, placebo-controlled trials are vital for assessing treatment efficacy. Developing a suitable placebo for injectable biologics presents unique challenges, particularly in matching the physical characteristics of the active drug without containing its active pharmaceutical ingredient. Methods: Our study developed a methodology for biologic placebo formulations, focusing on color and viscosity matching, in relevant chemical matrixes. A custom color deconvolution algorithm was used for precise color-matching, and sodium carboxymethyl cellulose (Na-CMC) was employed to adjust viscosity in different buffer systems. The interactions between buffers, color agents, and excipients were investigated to ensure consistency in physical properties. Stability testing was conducted under freeze/thaw and thermal stress conditions. Results: The color-matching algorithm successfully achieved visually indistinguishable results from the active drug, measured by an empirical parameter for color differences (ΔE values). Na-CMC was effective in matching the viscosity of biologic formulations, maintaining the desired physical appearance. Significant interactions between color agents and buffer systems influenced viscosity and osmolality. Stability tests confirmed that the placebo formulations retained their color, pH, and osmolality, with only minor viscosity changes after stress testing. Conclusions: Our study presents a systematic approach to biologic placebo development, providing a reliable framework for matching the color and viscosity of biologics. The methods and findings support the use of tailored excipients and color-matching algorithms to ensure clinical blinding in trials, enhancing the rigor of drug efficacy assessments and contributing to future placebo design in biologic drug development.

Indexed as

biologics placebocolor matchingplacebo formulationsodium carboxymethyl celluloseviscosity matching

Identifiers

PMID40583907
PMCPMC12202036

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.